endothelial growth factor-A (VEGF-A) gene.
-- Initiation of additional Phase 2 clinical trials of SB-509 in moderate
to severe DN (SB-509-701) and stem cell mobilization (SB-509-703). In
April, Sangamo announced the initiation of a randomized, single-blind,
placebo-controlled, repeat-dosing Phase 2 study designed to evaluate
the clinical safety and effects of repeat administration of SB-509 in
subjects that have moderate to severe DN (SB-509-701). In January
2008, Sangamo announced that it had initiated a randomized,
single-blind, placebo-controlled, multi-center Phase 2 clinical trial
(SB-509-703) in subjects with mild to moderate DN designed to evaluate
the pharmacokinetics of stem cell mobilization into the bloodstream
after treatment with varying doses of SB-509 as well as the clinical
safety and clinical effects of SB-509 administration.
-- Completion of enrollment of Phase 2 clinical trial of SB-509 for mild
to moderate DN (SB-509-601). In December, Sangamo announced that
enrollment was complete in a randomized, double-blind, repeat-dosing,
placebo-controlled, multi-center trial to evaluate SB-509 for the
treatment of mild to moderate DN. The company expects to have data
from this trial in the second half of 2008.
-- Establishment of major alliance with Sigma-Aldrich Corporation. In
July, as part of an agreement to develop and commercialize high value
laboratory research reagents based upon Sangamo's ZFP technology,
Sangamo received an upfront payment of $13.5 million which included
license fees and the purchase of one million shares of Sangamo stock.
Sangamo is also eligible to receive research funding, development and
commercial milestone payments of up to $24 m
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved